VFA
CLDX icon

Virtus Fund Advisers’s Celldex Therapeutics CLDX Stock Holding History

Virtus Fund Advisers’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$338K Buy
+7,931
New +$340K ﹤0.01% 422
2014
Q3 		– Sell
-508
Closed -$124K – 1297
2014
Q2 		$124K Buy
+508
New +$115K ﹤0.01% 1242

Other funds holding CLDX

CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KE
KLP Enterprises Branford, Connecticut $1.97M AUM
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Virtus Fund Advisers's CLDX Position: Q4 2017 in Review

Virtus Fund Advisers opened a new position in Celldex Therapeutics (CLDX) in Q4 2017: 7,931 shares worth $338K. The stake represents ﹤0.01% of the portfolio and ranks #422 among its holdings. This is a return to the name: Virtus Fund Advisers previously reported a position in CLDX as recently as Q2 2014.

Virtus Fund Advisers first reported a position in CLDX in Q2 2014 and has held it in 2 quarters since. 135 funds tracked by Wall St. Rank hold CLDX as of Q4 2017.

  • Virtus Fund Advisers held 7,931 shares of Celldex Therapeutics worth $338K as of Q4 2017.
  • Celldex Therapeutics was a new Virtus Fund Advisers position in Q4 2017.
  • Celldex Therapeutics made up ﹤0.01% of Virtus Fund Advisers's portfolio in Q4 2017, its #422 holding.
  • Virtus Fund Advisers first reported a position in Celldex Therapeutics in Q2 2014 and has held it in 2 quarters since.
  • 135 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.